Nektar Therapeutics (NKTR) Assets (2010 - 2026)

Nektar Therapeutics' Assets history runs 17 years deep, the most recent figure standing at $763.3 million for Q1 2026.

• In Q1 2026, Assets rose 197.87% year-over-year to $763.3 million; the TTM figure through Mar 2026 stood at $763.3 million (up 197.87% YoY), while the FY2025 annual figure was $280.4 million, down 7.72% from the prior year.
• Assets for Q1 2026 stood at $763.3 million, up from $280.4 million in the prior quarter.
• The five-year high for Assets was $1.0 billion in Q1 2022, with the low at $207.5 million in Q2 2025.
• The 5-year median for Assets is $398.0 million (2023), against an average of $496.1 million.
• The sharpest annual moves came in 2023 and 2026: Assets plunged 45.15% in 2023, then soared 197.87% in 2026.
• Nektar Therapeutics' Assets stood at $710.6 million in 2022, then sank by 43.99% to $398.0 million in 2023, then retreated by 23.66% to $303.8 million in 2024, then retreated by 7.72% to $280.4 million in 2025, then soared by 172.2% to $763.3 million in 2026.
• Business Quant data shows NKTR's Assets at $763.3 million in Q1 2026, $280.4 million in Q4 2025, and $301.3 million in Q3 2025.